Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration
Top Cited Papers
- 1 September 2015
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 122 (9), 1837-1845
- https://doi.org/10.1016/j.ophtha.2015.05.010
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATIONRetina, 2014
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab InjectionsOphthalmology, 2014
- EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASESRetina, 2014
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZONOphthalmology, 2013
- Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age‐related macular degenerationClinical & Experimental Ophthalmology, 2013
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year ResultsOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006